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Abstract
Background: Small airway narrowing is an important pathology which impacts lung function in chronic
obstructive pulmonary disease (COPD). The accumulation of fibroblasts and myofibroblasts contribute to
inflammation, remodeling and fibrosis by production and release of mediators such as cytokines, profibrotic factors
and extracellular matrix proteins. This study investigated the effects of the phosphodiesterase 4 inhibitor roflumilast,
combined with the long acting b2 adrenergic agonist indacaterol, both approved therapeutics for COPD, on
fibroblast functions that contribute to inflammation and airway fibrosis.
Methods: The effects of roflumilast and indacaterol treatment were characterized on transforming growth factor
b1 (TGFb1)-treated normal human lung fibroblasts (NHLF). NHLF were evaluated for expression of the profibrotic
mediators endothelin-1 (ET-1) and connective tissue growth factor (CTGF), expression of the myofibroblast marker
alpha smooth muscle actin, and fibronectin (FN) secretion. Tumor necrosis factor-a (TNF-a) was used to induce
secretion of chemokine C-X-C motif ligand 10 (CXCL10), chemokine C-C motif ligand 5 (CCL5) and granulocyte
macrophage colony-stimulating factor (GM-CSF) from NHLF and drug inhibition was assessed.
Results: Evaluation of roflumilast (1-10 μM) showed no significant inhibition alone on TGFb1-induced ET-1 and
CTGF mRNA transcripts, ET-1 and FN protein production, alpha smooth muscle expression, or TNF-a-induced
secretion of CXCL10, CCL5 and GM-CSF. A concentration-dependent inhibition of ET-1 and CTGF was shown with
indacaterol treatment, and a submaximal concentration was chosen for combination studies. When indacaterol (0.1
nM) was added to roflumilast, significant inhibition was seen on all inflammatory and fibrotic mediators evaluated,
which was superior to the inhibition seen with either drug alone. Roflumilast plus indacaterol combination
treatment resulted in significantly elevated phosphorylation of the transcription factor cAMP response element-
binding protein (CREB), an effect that was protein kinase A-dependent. Inhibition of protein kinase A was also
found to reverse the inhibition of indacaterol and roflumilast on CTGF.
Conclusions: These results demonstrate that addition of roflumilast to a LABA inhibits primary fibroblast/
myofibroblast function and therapeutically this may impact lung fibroblast proinflammatory and profibrotic
mediator release which contributes to small airway remodeling and airway obstruction in COPD.
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Fixed airway obstruction in chronic obstructive pulmon-
ary disease (COPD) is characterized by small airway nar-
rowing which can sometimes lead to airway occlusion.
This has a profound influence on lung function by redu-
cing the rate of emptying of air from the lungs [1].
Recently it has also been reported that narrowing and
loss of small airways proceeds emphysematous destruc-
tion in COPD patients [2]. The pathology of small air-
way disease includes thickening of the airway smooth
muscle, increased inflammatory cell recruitment,
mucous production and accumulation of fibroblasts/
myofibroblasts [3-5]. These resident cells promote
inflammation, remodeling and fibrosis by release of
inflammatory molecules such as cytokines, production
of profibrotic factors, and secretion and deposition of
extracellular matrix proteins (ECM).
The novel anti-inflammatory phosphodiesterase-4
(PDE4) inhibitor roflumilast (Daxas
®; Daliresp™)h a s
recently been approved in the US and EU for GOLD
stage 3 and 4 COPD patients. In Europe, Daxas
® is indi-
cated for maintenance treatment in severe COPD
patients with chronic bronchitis and a history of exacer-
bations as an add-on to bronchodilator treatment
(http://www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/Pulmonary-Allergy-
DrugsAdvisoryCommittee/UCM207377.pdf). Long acting
b2 adrenergic agonists (LABA) have been used as the
standard of care for asthma and COPD to provide
bronchodilation and symptom relief [6,7]. PDE4 inhibi-
tors and LABA are both known modulators of intracel-
lular cAMP levels in a variety of cells. PDE4 inhibitors
maintain baseline levels of cAMP by inhibiting the
hydrolysis of cAMP to AMP, while LABA induce high
levels of cAMP through a G protein-coupled receptor
mechanism [8,9]. Increased cAMP leads to activation of
the serine-threonine kinase protein kinase A (PKA),
with subsequent activation of the transcription factor
cAMP response element-binding protein (CREB) by
phosphorylation on Ser-133. This complementary
mechanism of action for both compounds suggests that
increased or sustained levels of cAMP can lead to altera-
tions in cell functions through CREB-dependent
mechanisms, either directly (by binding to cAMP
responsive elements (CRE) in the promoter region alter-
ing transcription) or indirectly (by association with and
sequestration of the cofactor CREB binding protein
(CBP)) [10,11].
PDE4 inhibitors have been shown to decrease early
stage inflammation and fibrosis in a bleomycin-induced
fibrosis model using preventative and therapeutic dosing
regimens [12,13]. In vitro evidence using roflumilast N-
oxide or roflumilast have shown little to modest effects
on lung fibroblast profibrotic mediator production and
alpha smooth muscle actin (aSMA) expression, while
inhibition was significantly augmented indirectly by
endogenous PGE2 generation [14,15].
Transforming growth factor b1( T G F b1) is a well
characterized profibrotic molecule that functions in nor-
mal wound healing, and can induce differentiation of
fibroblasts to myofibroblasts [16]. Myofibroblasts have a
more contractile phenotype, express aSMA, secrete
ECM proteins and cytokines, and profibrotic molecules
like endothelin-1 (ET-1) and connective tissue growth
factor (CTGF) [17,18]. Under pathological conditions,
excessive production of these factors can lead to lung
remodeling and inflammation which may impact lung
function [19,20]. In the present studies we employed a
TGFb1-driven model of myofibroblast differentiation to
investigate the effects roflumilast in combination with
indacaterol on myofibroblast expression and production
of ET-1, CTGF, aSMA, and FN as well as release of
cytokines in response to proinflammatory cytokine
stimulation.
Materials and methods
Materials
Reagents used were obtained from: RPMI and BSA
(Invitrogen, Car l s b a d ,C A ) ,T G F b1a n dT N F a (R&D
Systems, Minneapolis, MN), H89 and DMSO (Sigma-
Aldrich, St. Louis, MO). Compounds were synthesized
in Gilead Sciences laboratories.
Normal human lung fibroblast cell culture
Normal human lung fibroblasts (Lonza Walkersville Inc.,
Walkersville, MD) were routinely cultured in FGM-2
complete media (Lonza), 5% CO2,3 7 ° C ,a n du s e da t
passage 2-5 for experimentation. For experimentation,
NHLF were cultured to subconfluence, starved in RPMI
+ 0.1% BSA overnight, pretreated with compound for 1
h, and stimulated with 10 ng/mL transforming growth
factor-b1( T G F b1) for 6 h (RNA), 24 h (ET-1 produc-
tion) or 48 h (FN production and aSMA expression).
For experiments with H89, inhibitor was added 30 min
before compound pretreatment. All experimental groups
were performed in triplicate.
Transcript quantitation
Cell lysates were generated at 55°C for 30 min (Quanti-
gene Plex 2.0 Custom Reagent System, Affymetrix, Fre-
mont, CA), and run on a Luminex bead-based custom
multiplex according to manufacturer’si n s t r u c t i o n s .
Median fluorescence intensity (MFI) were generated for
each target and normalized to housekeeping genes, pep-
tidylprolyl isomerase B (PPIB) or hypoxanthine phos-
phoribosyltransferase (HPRT1), which were chosen to
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was calculated as compared to non-stimulated control.
Endothelin-1 quantitation
ET-1 production was quantitated by use of QuantiGlo
ELISA kit (R&D Systems, Inc.), according to manufac-
turer’s instructions. Results were calculated in pg/mL
based on a standard curve, and normalized to cell
number.
Fibronectin quantitation
FN production was quantitated by use of QuantiMatrix
ELISA (Millipore), run according to manufacturer’s
instructions. Results were calculated in ng/mL based on
a standard curve, and percentage of control calculated
from TGFb1 stimulated DMSO treated cells.
a-Smooth muscle actin expression
Cells were trypsinized, fixed (fix buffer 1, 10 min, 37°C,
BD Biosciences, San Jose, CA), permeabilized (perm buf-
fer III, 30 min, 4°C, BD Biosciences), stained with an
anti-aSMA-FITC antibody (Abcam, Cambridge, MA)
and visualized on a LSR II flow cytometer (BD Bios-
ciences). MFI was determined and percentage of control
calculated from TGFb1 stimulated DMSO treated cells.
pCREB quantitation
Cells were serum starved and were pretreated for 30
min with H89 (10 uM) or DMSO (0.1%), followed by
roflumilast and/or indacaterol treatment or DMSO
(0.1%) for 30 min, 37°C, washed with cold PBS and then
lysed on ice for 20 min (Millipore MAP Cell Signaling
kit, Millipore). Lysates werea n a l y z e df o rp C R E Bw i t h
Luminex bead-based assay (Milliplex MAP Phospho
CREB (Ser133) MAPmate, Millipore), as measured by
MFI. Results were calculated as percentage of DMSO
control.
CXCL10, CCL5 and GM-CSF secretion
Cells were serum starved, pretreated with compound or
DMSO (0.1%, 1 h), stimulated with TNFa (24 h, 10 ng/
mL) and cell supernatants run in a Luminex bead-based
assay, according to manufacturer’s instructions (Milli-
pore). Results were calculated in pg/mL based on a stan-
dard curve, and percentage inhibition calculated relative
to TNFa-stimulated DMSO control.
Statistics
IC50 data for the effect of indacaterol alone on ET-1 and
CTGF protein and transcript levels represents the arith-
metic mean ± SEM. IC50 data for cytokine inhibition
represents the geometric mean with 95% confidence
intervals Statistical analysis used a paired two-tailed Stu-
dent’s t-test or repeated one way ANOVA with Tukey’s
post hoc test. Results where the p-value was < 0.05 were
considered significant (GraphPad Software, San Diego,
CA).
Results
Addition of indacaterol to roflumilast inhibits TGFb1-
induced ET-1
A panel of candidate genes involved in fibrosis and
wound healing was assessed in a time- and concentra-
tion-dependent manner after TGFb1 treatment of
NHLF. These studies showed that gene induction
occurred at 2, 6 and 24 hours after TGFb1t r e a t m e n t ,
b u tt h a ta6h o u rt r e a t m e n tw i t hT G F b1 was optimal
for maximal gene induction (data not shown). Further
characterization of TGFb1-induced transcripts showed a
robust upregulation for CTGF, ET-1 and VEGF (19.4 ±
5.9, 13.6 ± 2.8, 7.5 ± 1.1 fold induced, respectively).
Induction of other genes examined was in the 1-3 fold
range, with no induction of TNFa or collagen 1A2
(COL1A2) seen (Table 1). Of the three most highly
induced genes, VEGF was determined to be insensitive
to indacaterol inhibition (data not shown), therefore
further characterization of indacaterol and roflumilast
inhibition of ET-1 and CTGF was performed.
TGFb1 stimulation of NHLF resulted in an upregula-
tion of ET-1 transcript levels of 9.4 ± 0.5 fold compared
to non-stimulated control cells. Evaluation of the LABA
indacaterol demonstrated a concentration-dependent
inhibition of ET-1, with an IC50 of 0.2 nM and maximal
inhibition of 72.0 ± 0.3% (Figure 1A). ET-1 protein pro-
duction was induced by TGFb1t r e a t m e n t ,w i t ha
change from 0.7 ± 0.4 pg/mL to 8.4 ± 0.8 pg/mL for
non-stimulated versus TGFb1 stimulated NHLF, respec-
tively. Indacaterol inhibited protein production in a con-
centration-dependent manner with an IC50 of 80.6 pM,
and concentrations of 10 nM indacaterol and above
driving levels of ET-1 down to baseline (Figure 1B).
Based on these findings for indacaterol on both ET-1
transcript and protein levels, a concentration of 0.1 nM
indacaterol was chosen that gave an IC30-40 to further
characterize combination treatment with roflumilast.
For combination treatment studies, TGFb1 stimulation
increased ET-1 transcript levels by 15.2 ± 2.9 fold com-
pared to non-stimulated controls. Neither roflumilast
nor indacaterol (0.1 nM) alone led to a statistically sig-
nificant inhibition of ET-1 transcript, although there
was a trend for inhibition with indacaterol. When
assessed together, indacaterol (0.1 nM) plus 1 or 10 uM
roflumilast combination treatment demonstrated 71.7 ±
1.1% (p < 0.01) and 74.5 ± 1.1% (p < 0.01) inhibition
respectively, which was greater than either agent alone
(Figure 1C).
Further characterization of ET-1 protein production
demonstrated an increase from 2.2 ± 0.7 pg/mL to
Tannheimer et al. Respiratory Research 2012, 13:28
http://respiratory-research.com/content/13/1/28
Page 3 of 1120.5 ± 3.2 pg/mL for non-stimulated versus TGFb1s t i -
mulated NHLF. Roflumilast treatment alone (1 and 10
μM) inhibited ET-1 secretion by 11.1 ± 2.7% and 27.6
± 3.2% of control, respectively, while indacaterol (0.1
nM) inhibited by 43.3 ± 1.5% (p < 0.05). Similar to the
results observed with ET-1 transcript levels, when
indacaterol (0.1 nM) was added to roflumilast treat-
ment (1 and 10 μM), the inhibition of ET-1 protein
secretion was more pronounced than with either agent
alone, with inhibition of 78.3 ± 4.0% (p < 0.001) and
85.7 ± 3.6% (p < 0.001) of control, respectively (Figure
1D).
Table 1 TGFb1-induced gene induction in NHLF (mean fold increase over non-stimulated)
CTGF TNFAa ET-1 VEGF aSMA TIMP1 TIM3 FN COL1A1 COL1A2
19.4 ± 5.9 NI 13.6 ± 2.8 7.5 ± 1.1 2.9 ± 0.8 1.5 ± 0.05 3.3 ± 0.7 1.3 ± 0.3 1.9 ± 0.4 NI
RNA was made 6 h after TGFb1 (10 ng/mL) treatment, and data represents the mean ± SEM of MFI normalized to housekeepers (PPIB, HPRT1), and fold induction
calculated versus non-stimulated control (n = 2-3). NI = not induced. Connective tissue growth factor (CTGF), tumor necrosis factor alpha (TNFa), endothelin-1
(ET-1), vascular endothelial growth factor (VEGF), alpha smooth muscle action (aSMA), tissue inhibitors of metalloproteinase (TIMP), fibronectin (FN), collagen 1a1,
1a2 (COL1A1, 1A2).
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Figure 1 Effect of roflumilast and indacaterol on TGFb1-induced ET-1 transcript (A, C) and protein (B, D) from NHLF. (A, C) NHLF were
pretreated with compound or vehicle control for 1 h and RNA was made 6 h after TGFb1 (10 ng/mL) treatment. Data represents the MFI
normalized to HPRT1 and fold induction calculated versus non-stimulated control. All data represent mean ± SEM for n = 3 (A), and n = 8 (C)
experiments, run in triplicate. (B, D) NHLF were pretreated with compound or vehicle control for 1 h and conditioned medium was collected 24
h after TGFb1 (10 ng/mL) treatment and quantitated for ET-1 protein secretion. All data represent mean ± SEM for n = 3 (B), and n = 6 (D)
experiments, run in triplicate. ROF: roflumilast, INDA: indacaterol. *p < 0.05, **p < 0.01, and ***p < 0.001 as compared to TGFb1 vehicle-treated
cells, ##p < 0.01 ###p < 0.001 as compared to roflumilast treated cells, &p < 0.05 as compared to indacaterol treated cells.
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induced CTGF in a PKA-dependent manner
TGFb1 stimulation caused an upregulation of CTGF
transcript levels of 14.6 ± 2.7 fold compared to non-sti-
mulated controls. Indacaterol demonstrated a concentra-
tion-dependent inhibition of CTGF, with an IC50 of 57.4
pM and maximal inhibition of 73.5 ± 0.4%. Indacaterol
at 0.1 nM caused 36.6 ± 2.2% inhibition, within the
same range seen for ET-1 transcript and protein inhibi-
tion at this concentration (Figure 2A).
In combination studies, CTGF transcript levels were
upregulated 9.0 ± 1.0 fold following TGFb1s t i m u l a t i o n .
Roflumilast alone caused a 9.9 ± 1.0% decrease in CTGF
transcript at the highest concentration tested (10 μM).
Indacaterol (0.1 nM) had no significant effect alone, but
in combination with roflumilast at both 1 or 10 μM
caused a significant decrease in transcript levels com-
pared to control, with 47.8 ± 1.1% (p < 0.001) and 52.7
± 1.1% (p < 0.001) inhibition, respectively (Figure 2B).
To interrogate the mechanism of action for the super-
ior inhibition seen with roflumilast plus indacaterol
treatment, addition of the PKA inhibitor H89 was evalu-
ated. As previously seen, roflumilast alone produced
very little inhibition of CTGF transcript levels and the
addition of H89 had not effect (Figure 2C). Indacaterol
(0.1 nM) led to inhibition of CTGF by 38% and this was
completely reversed by H89 treatment (p < 0.05). Inda-
caterol (0.1 nM) in combination with roflumilast
strongly inhibited CTGF, an effect that was almost com-
pletely blocked by H89 addition, with 90.1 ± 3.8% (p <
0.01) and 89.4 ± 7.9% (p < 0.05) of control at 1 and 10
μM, respectively.
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Figure 2 Roflumilast and indacaterol inhibition of CTGF transcript is PKA-dependent. For all experiments, NHLF were pretreated with
compound or vehicle control for 1 h and RNA was made 6 h after TGFb1 (10 ng/mL) treatment. (C) For experiments with H89 (10 μM), inhibitor
was added 30 min before compound pretreatment, with open bars (+H89) and checked bars (-H89) treatment. All data represents the MFI
normalized to PPIB and fold induction calculated versus non-stimulated control. The data represent the mean ± SEM for n = 5 (A), n = 8 (B) and
n = 3 (C) experiments, run in triplicate. ROF: roflumilast, INDA: indacaterol. (B) ***p < 0.001 as compared to TGFb1 vehicle-treated cells, ##p <
0.01 and ###p < 0.001 as compared to roflumilast treated cells. (C) *p < 0.05, **p < 0.01 as compared to H89 negative control.
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Page 5 of 11Indacaterol and roflumilast plus indacaterol increase
phosphorylated CREB
Roflumilast treatment (0.001-10 μM) resulted in no
increased pCREB at any concentration tested (Figure
3A). Indacaterol treatment however caused a concentra-
tion-dependent increase in pCREB, with 10 nM indaca-
terol eliciting an increase of 134.6 ± 22.4% above
control (p < 0.05). Further characterization of roflumi-
last treatment again showed little effect on pCREB
(maximal 16.8% above control), while indacaterol (0.1
nM) increased pCREB with a 23% increase over control
(Figure 3B). When 0.1 nM indacaterol was combined
with roflumilast at 0.001, 1 or 10 μM, pCREB was
increased by 56 ± 23% (p < 0.05), 128 ± 27% (p < 0.001)
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Figure 3 Indacaterol and roflumilast increased pCREB in a PKA-dependent manner. NHLF were treated with compound (30 min) (A), or
pretreated with - (open bars) or + H89 (hatched bars) followed by compound treatment (30 min) (B), and MFI for pCREB determined. Data is
reported as percentage of vehicle control, mean ± SEM from n = 4-6 experiments. ROF: roflumilast, INDA: indacaterol. * p < 0.05, **p < 0.01, ***p
< 0.001 compared to vehicle treated cells, &p < 0.05 as compared to H89 negative control.
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Page 6 of 11and 125 ± 38% (p < 0.01) over DMSO control cells,
respectively. Use of H89 reduced pCREB to near basal
levels as compared to no H89 treatment.
Modulation of aSMA expression and FN secretion in
NHLF by roflumilast and indacaterol combination
After TGFb1 treatment, fibroblasts acquire a more con-
tractile phenotype, and this is characterized by expres-
sion of aSMA, accompanied by an increased potential
to secrete ECM proteins. Treatment of NHLF with
TGFb1 caused a 10.4 ± 5.5 fold upregulation of aSMA
expression. Roflumilast (1 and 10 μM) and indacaterol
(0.1 nM) alone failed to inhibit aSMA expression
(Figure 4A). In combination, roflumilast plus indacaterol
inhibited aSMA expression 29.1 ± 11.8% and 47.8 ±
8.9% (p < 0.05) of control at 1 and 10 μM roflumilast
plus indacaterol (0.1 nM), respectively.
Evaluation of the production of the ECM protein FN
showed that after treatment of NHLF with TGFb1, FN
levels increased from 4580 ± 2029 ng/mL to 8700 ±
3693 ng/mL. Treatment with either roflumilast (1 or 10
μM) or indacaterol (0.1 nM) alone caused no significant
inhibition of FN secretion (Figure 4B). Roflumilast (1 or
10 μM) in combination with indacaterol (0.1 nM) how-
ever demonstrated inhibition of 79.4 ± 10.2% (p < 0.01)
and 69.3 ± 3.8% (p < 0.001) of control respectively.
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Figure 4 Effect of roflumilast and indacaterol on TGFb1-induced aSMA expression and FN secretion in NHLF. (A) NHLF were pretreated
with compound or vehicle control for 1 h, treated with TGFb1 (10 ng/mL) for 48 h, and aSMA expression quantitated by flow cytometry. Data
is reported as the percentage of TGFb1 vehicle-treated cells, mean ± SEM for n = 4. (B) NHLF were pretreated with compound or vehicle control
for 1 h, treated with TGFb1 (10 ng/mL) for 48 h and FN secretion quantitated. Data is reported as the percentage of TGFb1 vehicle-treated cells,
mean ± SEM for n = 4-6. ROF: roflumilast, INDA: indacaterol. *p < 0.05, **p < 0.01, ***p < 0.001 as compared to TGFb1 vehicle-treated cells, #p <
0.05 and ###p < 0.001 as compared to roflumilast treated cells, &p < 0.05 and &&p < 0.01 as compared to indacaterol treated cells.
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on TNFa-induced CXCL10, CCL5 and GM-CSF secretion
Conditioned media from TNFa- treated NHLF was
assessed on a panel of cytokines, where GM-CSF, CCL5
and CXCL10 were found to be increased to 228 ± 12,
21042 ± 513, and 6220 ± 241 pg/mL at 24 h post-stimu-
lation, respectively. Roflumilast or indacaterol alone, and
in combination, were assessed for their ability to inhibit
TNFa-induced production of these three cytokines from
NHLF. Indacaterol caused a potent concentration-
dependent inhibition of all three cytokines, with IC50
values of 0.1 nM (CI 0.03-0.4 nM), 0.02 nM (CI 0.007-
0.06 nM), and 0.09 nM (CI 0.04-0.2 nM) for GM-CSF,
CCL5 and CXCL10, respectively (Figure 5A). A submax-
imal concentration of 0.1 nM indacaterol was chosen to
assess the effects of roflumilast in combination. Roflumi-
last alone showed little to modest effects on the inhibi-
tion of GM-CSF, CCL5 and CXCL10, with no more
than 20% inhibition seen up to 0.1 μM( F i g u r e5 B - D ) .
Roflumilast in combinationw i t h0 . 1n Mi n d a c a t e r o l
caused a concentration-dependent inhibition of all three
cytokines, greater than roflumilast treatment alone. In
combination the maximal inhibition for GM-CSF shifted
from 18.8 ± 6.6% to 57.5 ± 7.8% (p < 0.01), for CCL5
from 17.1 ± 6.2% to 89.4 ± 2.5% (p < 0.001), and for
CXCL10 from 7.0 ± 3.8% to 58.1 ± 8.4% (p < 0.001), as
compared to roflumilast alone. The IC50 for roflumilast
plus indacaterol (0.1 nM) treatment was 1.0 nM (CI 0.1
-7 . 0n M ) ,0 . 2n M( C I0 . 1-0 . 3n M )a n d0 . 4n M( C I
0.07 - 2.2 nM) for GM-CSF, CCL5 and CXCL10,
respectively.
Discussion
T h eu s eo ft h eP D E 4i n h i b i t o rr o f l u m i l a s tp r o v i d e sa
novel therapeutic option that improves lung function in
COPD patients, and preclinically has been shown to
produce a variety of anti-inflammatory effects [21-23].
While some studies have begun to address the effects
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Figure 5 Indacaterol, roflumilast and combination effects on TNFa -induced cytokines GM-CSF, CCL5 and CXCL10 from NHLF. (A) Data
represents the mean ± SEM inhibition of indacaterol for GM-CSF (open circle), CCL5 (open square) or CXCL10 (open triangle) released from
NHLF compared to vehicle treated cells following stimulation with TNFa (10 ng/mL, 24 h), n = 6. (B-D) Data represents the mean ± SEM
inhibition of GM-CSF (B), CCL5 (C) or CXCL10 (D) released from NHLF compared to vehicle-treated cells following stimulation with TNFa (10 ng/
mL, 24 h). The open circles represent roflumilast (n = 8 donors), open square represents indacaterol at 0.1 nM (n = 8 donors) and closed circles
represent roflumilast in the presence of 0.1 nM indacaterol (n = 4 donors). INDA: indacaterol. **p < 0.01, ***p < 0.001 as compared to roflumilast
alone.
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Page 8 of 11that roflumilast has on resident lung cells, our studies
extend those findings by examining the effect roflumilast
may have when added onto existing b2 agonist treat-
ment in the context of small airway disease.
TGFb1 has been well characterized on fibroblasts for
its effects in wound healing [24], but excessive levels of
TGFb1, as seen in chronic disease states, is likely to
contribute to the inflammation and remodeling seen in
small airway disease. Indeed, increased production of
TGFb1 from the epithelium in the small airways of
COPD patients has been seen and correlates with small
airway obstruction [25]. In vivo, the intratracheal admin-
istration of TGFb1 led to increased collagen deposition
in the airways and airway hyperreactivity [26]. TGFb1-
driven fibrosis can be further amplified by the direct
induction of other profibrotic molecules, ET-1 and
CTGF [17,18,27,28]. Antagonists of ET-1 have been
evaluated in clinical trials for use in idiopathic pulmon-
ary fibrosis (IPF) with limited success, but there is
clearly a biological rationale for ET-1 in pulmonary
fibrosis which still supports antagonism and/or
decreased levels of protein as providing a potential ther-
apeutic advantage [29,30]. Our studies show that indaca-
terol caused a concentration-dependent inhibition of
ET-1 and CTGF. When a submaximal concentration of
indacaterol was combined with roflumilast there was an
augmentation of inhibition of ET-1 transcript levels and
protein production, with a similar pattern of inhibition
on CTGF transcript levels. The fact that roflumilast plus
indacaterol combination treatment reduced TGFb1-dri-
ven increases in ET-1 and CTGF provides strong evi-
dence for effects on profibrotic mediators upstream of
therapeutic interventions with ET-1 and/or CTGF
antagonists. This combinati o nt r e a t m e n tc o u l dl e a dt o
more pronounced effects on profibrotic mediator release
because of the broad effect it appears to have on key
mediators involved in this process.
Previous studies looking at the effects of roflumilast
on anti-remodeling events have demonstrated a modest
effect on collagen gel contraction and FN secretion
from collagen embedded NHLF [15]. While in our stu-
dies high concentrations of roflumilast had little effect,
our results are in agreement with the observation that
when roflumilast is combined with other agents that can
elevate cAMP, an enhanced inhibition of mediators
involved in fibroblast function is observed [14]. While
PGE2 can lead to enhanced inhibition of PDE4 inhibi-
tors on fibroblast function, due to either increased endo-
genous PGE2 production or exogenous addition [14,15],
in our assay system using NHLF we saw no direct
increase in PGE2 to point to this as a possible mechan-
ism of action for enhanced inhibition (data not shown).
TGFb1 can signal downstream of its receptor through
activation of the transcription factor family of Smad
proteins [31]. Evaluation of cAMP elevating agents that
can inhibit TGFb-induced pathways have shown that
Smad phosphorylation and translocation to the nucleus
remain intact, with the mechanism of action being inde-
pendent of direct effects on Smad signaling [10,32]. In
the present study, we showed that roflumilast plus inda-
caterol combination treatment elevates pCREB in NHLF
and the phosphorylation is dependent on activation of
PKA, as demonstrated by use of the PKA inhibitor H89.
We go on to extend these findings and show that the
inhibitory affect of indacaterol and roflumilast plus inda-
caterol combination treatment on CTGF transcript
levels is PKA-dependent as well. While some effects of
pCREB are due to CRE binding, others have shown that
the association of pCREB with CREB-binding protein
(CBP)/p300 serves as a limiting cofactor for other tran-
scription factors such as Smad 3/4 and NF-B
[10,11,33]. While the cAMP/PKA pathway is a pivotal
activator of pCREB, there is also evidence for down-
stream effects on both Raf-1 and ERK1/2 phosphoryla-
tion [34]. A more extensive evaluation of the
mechanism of action downstream of pCREB would need
to be done in order understand the inhibition observed
in our studies.
Fibroblasts can both respond to, and secrete proin-
flammatory cytokines. The well characterized proinflam-
matory cytokine, TNFa, in our model system induced
secretion of CXCL10, CCL5 and GM-CSF. CXCL10 and
CCL5 are chemokines that are important for monocyte
and T cell recruitment to the lung, and GM-CSF is
responsible for myeloid survival, differentiation and acti-
vation [35,36]. CCL5 has been found to be upregulated
in the airways and sputum of COPD patients during
exacerbations [37], while CXCL10 levels have been seen
to be elevated in the lungs of COPD patients [38]. The
ability to inhibit the secretion of these cytokines from
resident lung fibroblasts is likely to impact the accumu-
lation of immune cells in the local environment, and
lead to further remodeling of the small airways.
CXCL10, CCL5 and GM-CSF were all sensitive to inda-
caterol inhibition in a concentration-dependent manner.
Addition of roflumilast to a submaximal concentration
of indacaterol further increased levels of cytokine inhibi-
tion, more than either agent alone. There is most likely
a difference in the regulatory mechanisms driving the
inhibition of these three different cytokines in NHLF,
especially since CCL5 inhibition can be driven almost
completely to baseline levels, and the CCL5 promoter
region contains a NF-B binding site and a CRE [39]. It
has previously been shown that cAMP elevators, PGE2
and forskolin, can reduce CCL5 production in a H89-
dependent manner [40]. While we did not directly
investigate the mechanism of action for inhibition with
roflumilast plus indacaterol combination, there is likely
Tannheimer et al. Respiratory Research 2012, 13:28
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Page 9 of 11to be an overlap of mechanisms that works in tandem to
give better than additive effects.
We are the first to report the characterization of the
combination of a PDE4 inhibitor with a LABA on pri-
mary normal human lung fibroblasts, and demonstrate
an enhanced effect by addition of a PDE4 inhibitor to a
low concentration of beta-2 agonist on inhibition of
NHLF cell function as they relate to proinflammatory
and profibrotic mechanisms. It is possible therefore that
therapeutically the addition of roflumilast to LABA
treatment could impact lung fibroblast proinflammatory
and profibrotic functions in the small airways, a process
which contributes to fixed airway obstruction in COPD.
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